CONMED Extraordinary Items vs Total Revenue Analysis

CNMD Stock

USD 73.16 0.73 0.99%

CONMED financial indicator trend analysis is way more than just evaluating CONMED prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether CONMED is a good investment. Please check the relationship between CONMED Extraordinary Items and its Total Revenue accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CONMED. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

For information on how to trade CONMED Stock refer to our How to Trade CONMED Stock guide.

Extraordinary Items vs Total Revenue

Extraordinary Items vs Total Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of CONMED Extraordinary Items account and Total Revenue. At this time, the significance of the direction appears to have strong contrarian relationship.

The correlation between CONMED's Extraordinary Items and Total Revenue is -0.67. Overlapping area represents the amount of variation of Extraordinary Items that can explain the historical movement of Total Revenue in the same time period over historical financial statements of CONMED, assuming nothing else is changed. The correlation between historical values of CONMED's Extraordinary Items and Total Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Extraordinary Items of CONMED are associated (or correlated) with its Total Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Revenue has no effect on the direction of Extraordinary Items i.e., CONMED's Extraordinary Items and Total Revenue go up and down completely randomly.

Correlation Coefficient

-0.67

Relationship Direction	Negative
Relationship Strength	Weak

View All Relationships

Extraordinary Items

Total Revenue

Total revenue comprises all receipts CONMED generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Most indicators from CONMED's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into CONMED current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CONMED. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

For information on how to trade CONMED Stock refer to our How to Trade CONMED Stock guide.At present, CONMED's Enterprise Value is projected to increase significantly based on the last few years of reporting.

	2021	2022	2023	2024 (projected)
Gross Profit	568.0M	571.2M	643.1M	675.2M
Total Revenue	1.0B	1.0B	1.2B	1.3B

Gross Profit Total Revenue

CONMED fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Intangible Assets	Accounts Payable	Good Will	Common Stock Total Equity
Total Assets		0.96	0.78	0.97	0.68	0.39	0.95	0.53	-0.06	0.99	0.6	-0.06	0.95	0.67	0.98	0.94	0.79	0.97	0.98	0.83	0.94	0.41	0.84	0.96	0.88	0.7
Short Long Term Debt Total	0.96		0.67	0.93	0.53	0.14	1.0	0.37	-0.23	0.97	0.57	-0.23	0.84	0.47	0.99	0.86	0.66	0.87	0.99	0.78	0.82	0.43	0.84	0.96	0.9	0.48
Other Current Liab	0.78	0.67		0.84	0.43	0.34	0.66	0.21	0.0	0.73	0.43	0.0	0.74	0.46	0.72	0.88	0.67	0.85	0.75	0.87	0.85	0.24	0.47	0.73	0.57	0.54
Total Current Liabilities	0.97	0.93	0.84		0.58	0.32	0.92	0.38	-0.14	0.96	0.53	-0.13	0.91	0.57	0.95	0.97	0.78	0.97	0.97	0.89	0.94	0.48	0.75	0.96	0.82	0.62
Total Stockholder Equity	0.68	0.53	0.43	0.58		0.81	0.51	0.95	0.27	0.66	0.49	0.27	0.73	0.96	0.57	0.6	0.6	0.7	0.58	0.45	0.7	0.31	0.82	0.55	0.75	0.89
Property Plant And Equipment Net	0.39	0.14	0.34	0.32	0.81		0.11	0.82	0.57	0.33	0.21	0.57	0.55	0.9	0.23	0.4	0.54	0.5	0.24	0.21	0.56	0.16	0.44	0.22	0.3	0.92
Net Debt	0.95	1.0	0.66	0.92	0.51	0.11		0.35	-0.28	0.97	0.58	-0.28	0.83	0.45	0.99	0.85	0.62	0.86	0.98	0.78	0.8	0.44	0.83	0.96	0.9	0.45
Retained Earnings	0.53	0.37	0.21	0.38	0.95	0.82	0.35		0.39	0.51	0.4	0.39	0.62	0.94	0.4	0.4	0.51	0.54	0.4	0.23	0.55	0.16	0.72	0.39	0.59	0.86
Cash	-0.06	-0.23	0.0	-0.14	0.27	0.57	-0.28	0.39		-0.13	-0.4	1.0	0.0	0.36	-0.16	-0.01	0.39	-0.03	-0.15	-0.13	0.16	-0.22	0.06	-0.19	-0.16	0.4
Non Current Assets Total	0.99	0.97	0.73	0.96	0.66	0.33	0.97	0.51	-0.13		0.63	-0.13	0.93	0.63	0.99	0.9	0.73	0.95	0.99	0.81	0.9	0.41	0.86	0.97	0.9	0.65
Non Currrent Assets Other	0.6	0.57	0.43	0.53	0.49	0.21	0.58	0.4	-0.4	0.63		-0.4	0.55	0.45	0.58	0.47	0.22	0.59	0.58	0.41	0.44	0.13	0.48	0.53	0.61	0.39
Cash And Short Term Investments	-0.06	-0.23	0.0	-0.13	0.27	0.57	-0.28	0.39	1.0	-0.13	-0.4		0.0	0.36	-0.15	-0.01	0.39	-0.03	-0.15	-0.13	0.16	-0.22	0.06	-0.19	-0.16	0.4
Net Receivables	0.95	0.84	0.74	0.91	0.73	0.55	0.83	0.62	0.0	0.93	0.55	0.0		0.77	0.87	0.87	0.79	0.96	0.88	0.75	0.94	0.3	0.76	0.92	0.76	0.82
Common Stock Shares Outstanding	0.67	0.47	0.46	0.57	0.96	0.9	0.45	0.94	0.36	0.63	0.45	0.36	0.77		0.53	0.62	0.67	0.73	0.54	0.45	0.74	0.28	0.7	0.53	0.62	0.97
Non Current Liabilities Total	0.98	0.99	0.72	0.95	0.57	0.23	0.99	0.4	-0.16	0.99	0.58	-0.15	0.87	0.53		0.9	0.71	0.91	1.0	0.82	0.87	0.42	0.85	0.96	0.9	0.55
Inventory	0.94	0.86	0.88	0.97	0.6	0.4	0.85	0.4	-0.01	0.9	0.47	-0.01	0.87	0.62	0.9		0.85	0.96	0.92	0.93	0.97	0.5	0.71	0.9	0.77	0.66
Other Current Assets	0.79	0.66	0.67	0.78	0.6	0.54	0.62	0.51	0.39	0.73	0.22	0.39	0.79	0.67	0.71	0.85		0.81	0.73	0.76	0.91	0.23	0.62	0.76	0.57	0.74
Other Stockholder Equity	0.97	0.87	0.85	0.97	0.7	0.5	0.86	0.54	-0.03	0.95	0.59	-0.03	0.96	0.73	0.91	0.96	0.81		0.93	0.87	0.97	0.41	0.75	0.92	0.8	0.76
Total Liab	0.98	0.99	0.75	0.97	0.58	0.24	0.98	0.4	-0.15	0.99	0.58	-0.15	0.88	0.54	1.0	0.92	0.73	0.93		0.84	0.89	0.44	0.84	0.97	0.89	0.57
Property Plant And Equipment Gross	0.83	0.78	0.87	0.89	0.45	0.21	0.78	0.23	-0.13	0.81	0.41	-0.13	0.75	0.45	0.82	0.93	0.76	0.87	0.84		0.86	0.38	0.59	0.84	0.69	0.47
Total Current Assets	0.94	0.82	0.85	0.94	0.7	0.56	0.8	0.55	0.16	0.9	0.44	0.16	0.94	0.74	0.87	0.97	0.91	0.97	0.89	0.86		0.39	0.73	0.89	0.74	0.8
Short Term Debt	0.41	0.43	0.24	0.48	0.31	0.16	0.44	0.16	-0.22	0.41	0.13	-0.22	0.3	0.28	0.42	0.5	0.23	0.41	0.44	0.38	0.39		0.42	0.34	0.49	0.22
Intangible Assets	0.84	0.84	0.47	0.75	0.82	0.44	0.83	0.72	0.06	0.86	0.48	0.06	0.76	0.7	0.85	0.71	0.62	0.75	0.84	0.59	0.73	0.42		0.78	0.95	0.66
Accounts Payable	0.96	0.96	0.73	0.96	0.55	0.22	0.96	0.39	-0.19	0.97	0.53	-0.19	0.92	0.53	0.96	0.9	0.76	0.92	0.97	0.84	0.89	0.34	0.78		0.83	0.57
Good Will	0.88	0.9	0.57	0.82	0.75	0.3	0.9	0.59	-0.16	0.9	0.61	-0.16	0.76	0.62	0.9	0.77	0.57	0.8	0.89	0.69	0.74	0.49	0.95	0.83		0.55
Common Stock Total Equity	0.7	0.48	0.54	0.62	0.89	0.92	0.45	0.86	0.4	0.65	0.39	0.4	0.82	0.97	0.55	0.66	0.74	0.76	0.57	0.47	0.8	0.22	0.66	0.57	0.55

Click cells to compare fundamentals

CONMED Account Relationship Matchups

CONMED fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	1.8B	1.8B	1.8B	2.3B	2.3B	2.4B
Short Long Term Debt Total	768.8M	775.9M	684.7M	1.1B	991.3M	1.0B
Other Current Liab	64.8M	111.0M	126.2M	153.4M	206.1M	216.4M
Total Current Liabilities	188.1M	190.2M	196.6M	296.6M	310.7M	326.3M
Total Stockholder Equity	710.5M	709.0M	785.4M	745.5M	834.2M	428.2M
Property Plant And Equipment Net	118.9M	111.4M	108.9M	115.6M	137.3M	92.9M
Net Debt	743.0M	748.5M	663.8M	1.0B	967.0M	1.0B
Retained Earnings	470.8M	457.4M	496.6M	412.6M	452.5M	246.1M
Cash	25.9M	27.4M	20.8M	28.9M	24.3M	17.2M
Non Current Assets Total	1.4B	1.3B	1.3B	1.7B	1.7B	1.8B
Non Currrent Assets Other	102.3M	96.8M	98.8M	93.9M	79.5M	83.5M
Cash And Short Term Investments	25.9M	27.4M	20.8M	28.9M	24.3M	17.5M
Net Receivables	189.1M	177.2M	183.9M	191.3M	242.3M	254.4M
Common Stock Shares Outstanding	29.5M	29.5M	32.2M	30.0M	31.5M	25.9M
Liabilities And Stockholders Equity	1.8B	1.8B	1.8B	2.3B	2.3B	2.4B
Non Current Liabilities Total	876.5M	852.4M	783.9M	1.3B	1.2B	1.2B
Inventory	164.6M	194.9M	231.6M	332.3M	318.3M	334.2M
Other Current Assets	17.8M	17.3M	23.8M	28.6M	30.8M	32.3M
Other Stockholder Equity	298.6M	315.0M	342.7M	390.5M	431.5M	453.1M
Total Liab	1.1B	1.0B	980.6M	1.6B	1.5B	1.5B
Property Plant And Equipment Gross	118.9M	111.4M	372.6M	393.1M	412.9M	433.5M
Total Current Assets	397.4M	416.7M	460.1M	581.2M	615.6M	646.4M
Accumulated Other Comprehensive Income	(59.3M)	(63.7M)	(54.2M)	(57.9M)	(50.2M)	(47.7M)
Short Term Debt	13.6M	25.9M	12.2M	69.7M	16.4M	16.8M
Intangible Assets	532.8M	501.5M	471.0M	681.8M	649.5M	331.7M
Accounts Payable	56.0M	53.3M	58.2M	73.4M	88.2M	92.6M
Good Will	618.0M	618.4M	617.5M	815.4M	806.8M	430.8M
Other Liab	104.2M	102.5M	98.8M	258.7M	297.5M	312.3M
Other Assets	84.9M	103.6M	89.0M	85.8M	98.7M	103.6M
Long Term Debt	755.2M	734.8M	672.4M	985.1M	973.1M	1.0B
Treasury Stock	(80.7M)	(67.6M)	(54.1M)	(22.8M)	(20.5M)	(21.5M)
Property Plant Equipment	118.9M	111.4M	108.9M	115.6M	133.0M	129.3M
Current Deferred Revenue	53.7M	50.2M	60.5M	9.7M	(8.2M)	(7.8M)
Net Tangible Assets	(440.4M)	(410.9M)	(340.8M)	(751.7M)	(676.5M)	(642.7M)
Retained Earnings Total Equity	470.8M	457.4M	496.6M	412.6M	474.5M	467.3M
Long Term Debt Total	755.2M	735.2M	672.4M	985.1M	1.1B	1.2B
Capital Surpluse	379.3M	382.6M	396.8M	413.2M	475.2M	384.5M
Deferred Long Term Liab	74.5M	57.9M	68.5M	66.7M	60.1M	72.4M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ESRT	Empire State Realty
C	Citigroup
C	Citigroup

When determining whether CONMED is a strong investment it is important to analyze CONMED's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact CONMED's future performance. For an informed investment choice regarding CONMED Stock, refer to the following important reports:

How To Invest In CONMED

Details

Is CONMED Stock a good investment?

Details

What is CONMED's Net Worth?

Details

Largest Health Care Equipment & Supplies Companies

View

Largest Health Care Equipment & Services Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CONMED. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

For information on how to trade CONMED Stock refer to our How to Trade CONMED Stock guide.

You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.

Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CONMED. If investors know CONMED will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CONMED listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

2.14

Dividend Share

0.8

Earnings Share

4.22

Revenue Per Share

41.821

Quarterly Revenue Growth

0.04

The market value of CONMED is measured differently than its book value, which is the value of CONMED that is recorded on the company's balance sheet. Investors also form their own opinion of CONMED's value that differs from its market value or its book value, called intrinsic value, which is CONMED's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CONMED's market value can be influenced by many factors that don't directly affect CONMED's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between CONMED's value and its price as these two are different measures arrived at by different means. Investors typically determine if CONMED is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CONMED's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

CONMED Extraordinary Items vs Total Revenue Analysis

Extraordinary Items vs Total Revenue

Extraordinary Items vs Total Revenue Correlation Analysis

Correlation Coefficient

Extraordinary Items

Total Revenue

CONMED fundamental ratios Correlations

CONMED Account Relationship Matchups

High Positive Relationship

High Negative Relationship

CONMED fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Net Debt	+ 1.0	Short Long Term Debt Total
Cash And Short Term Investments	+ 1.0	Cash
Total Liab	+ 1.0	Non Current Liabilities Total
Non Current Assets Total	+ 0.99	Total Assets
Non Current Liabilities Total	+ 0.99	Short Long Term Debt Total
Total Liab	+ 0.99	Short Long Term Debt Total

Cash And Short Term Investments	- 0.4	Non Currrent Assets Other
Non Currrent Assets Other	- 0.4	Cash
Cash And Short Term Investments	- 0.28	Net Debt
Cash	- 0.28	Net Debt
Cash And Short Term Investments	- 0.23	Short Long Term Debt Total
Cash	- 0.23	Short Long Term Debt Total